Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health Inc (NQ: JAGX )

0.6550 -0.0097 (-1.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 370,917
Open 0.6523
Bid (Size) 0.6500 (13)
Ask (Size) 0.6685 (9)
Prev. Close 0.6647
Today's Range 0.6401 - 0.6850
52wk Range 0.4601 - 28.50
Shares Outstanding 171,350,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Canine and Child Cancer Research Advocates Call for Support as Capitol Hill "Goes to the Dogs"
Via ACCESSWIRE
European Pharmaceutical Industry Leader and Entrepreneur Massimo Radaelli, PhD Named Commander of the Italian Republic for Special Merits
Via ACCESSWIRE

Performance

YTD
-90.02%
-90.02%
1 Month
-3.61%
-3.61%
3 Month
-49.62%
-49.62%
6 Month
-92.20%
-92.20%
1 Year
-97.51%
-97.51%

More News

Read More
Jaguar Announces Over-Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
Board Certified Patient Advocate Stacey Tinianov, MPH, Joins Jaguar Health's Scientific Advisory Board
Via ACCESSWIRE
Take C.H.A.R.G.E. Registry Marks One-Year Anniversary on National Canine Cancer Awareness Day, With Database Grown 40%
Via ACCESSWIRE
Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Jaguar Health Reports First Quarter 2023 Financial Results
Via ACCESSWIRE
Jaguar Health Launches AI-powered Web Portal to Support Patient Access to Mytesi, the Company's FDA-approved Prescription Drug
Via ACCESSWIRE
Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
Jaguar Health to Present at Lytham Partners Spring 2023 Investor Conference & Participate in Animal Health Panel
Via ACCESSWIRE
Nasdaq Rises 75 Points; Tower Semiconductor Posts Upbeat Q1 Results
Via Benzinga
Filament Health's Q1 2023 Financial Results, Material Uncertainty On The Horizon
Via Benzinga
Crude Oil Rises 1.5%; Athenex Shares Plummet
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Napo Therapeutics Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress in Abu Dhabi
Via ACCESSWIRE
U.S. Veterinary Oncologists Participating in a New Survey Prefer Canalevia-CA1 Over the Current Standard of Care
Via ACCESSWIRE
Patient Enrollment Surpasses 90% in Jaguar Health's Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Canalevia-CA1, Jaguar Animal Health’s FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs, Now Available from Chewy
Via ACCESSWIRE
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates
Via ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Jaguar Health Provides Update on Monitoring Trading Activity to Identify Possible Illegal Short Selling
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.